Is Ebglyss in Shortage in 2026?

If you're a patient with moderate-to-severe atopic dermatitis who relies on Ebglyss (Lebrikizumab-lbkz), you may have heard rumors about shortages or had trouble getting your prescription filled. Let's cut through the confusion and give you the facts.

As of early 2026, Ebglyss is not listed on the FDA or ASHP drug shortage databases. That means there is no official nationwide shortage. However, many patients are still finding it difficult to locate — and there are real reasons for that.

Why Is Ebglyss Hard to Find If It's Not in Shortage?

The distinction between a formal drug shortage and limited availability is important. Here's why Ebglyss can be difficult to get even without being on a shortage list:

Specialty Pharmacy Distribution Only

Ebglyss is a biologic that requires refrigeration and special handling. It's not stocked at most retail pharmacies. Instead, it's dispensed through specialty pharmacies — a smaller, more controlled distribution channel. If you're trying to fill your prescription at a regular pharmacy, you'll likely be told it's not available.

New Drug, Growing Distribution

Ebglyss was only approved by the FDA in September 2024, making it less than two years old on the market. Its distribution network is still expanding. Not every specialty pharmacy has onboarded it yet, and some regions may have more limited access than others.

Insurance Barriers

Even when stock exists, insurance prior authorization and step therapy requirements can delay access by days or weeks. Many insurers require patients to try and fail Dupixent or other treatments before covering Ebglyss, creating a bottleneck that feels like a supply problem.

For a deeper dive, read why Ebglyss is so hard to find.

How Much Does Ebglyss Cost in 2026?

Cost is one of the biggest concerns for patients. Here's what you can expect:

• Without insurance: Approximately $2,500 to $3,800 per injection. During the loading phase (first month), you'll need more frequent injections, making the initial cost higher. Once on maintenance dosing (every 4 weeks), expect around $3,200 per month.
• With commercial insurance: Your copay will vary by plan, but many patients pay between $0 and $100 per injection with the Eli Lilly Ebglyss Savings Card.
• With Medicare/Medicaid: Coverage varies by plan. Medicare Part D may cover Ebglyss under specialty tier, but copays can be significant. Medicaid coverage varies by state.

For full cost-saving strategies, see how to save money on Ebglyss.

Are There New Options for Atopic Dermatitis in 2026?

The atopic dermatitis treatment landscape has grown significantly. In addition to Ebglyss, patients now have access to several systemic therapies:

• Dupixent (Dupilumab): The most established biologic for eczema, blocking IL-4 and IL-13
• Adbry (Tralokinumab): Another IL-13 inhibitor biologic, similar to Ebglyss
• Rinvoq (Upadacitinib): An oral JAK inhibitor taken daily
• Cibinqo (Abrocitinib): Another oral JAK inhibitor option

Having multiple options means you and your doctor can find the right treatment even if one medication isn't available. Read our full comparison in alternatives to Ebglyss.

How to Find Ebglyss in Stock Right Now

If you need Ebglyss and want to check availability, here are your best steps:

1. Use Medfinder to search for pharmacies near you that have Ebglyss in stock.
2. Contact your specialty pharmacy directly to confirm availability and schedule delivery.
3. Ask your dermatologist's office — they often know which specialty pharmacies have the most reliable stock.
4. Start insurance paperwork early — don't wait until you need your next injection to begin the prior authorization process.

For detailed tips, read our guide on how to find Ebglyss in stock near you.

What About Ebglyss's History With the FDA?

Ebglyss had a bumpy road to approval. In September 2023, the FDA declined to approve the drug — not because of safety or efficacy concerns, but due to issues found during an inspection of a contract manufacturing facility. It took a full year to resolve those manufacturing compliance issues before the FDA finally granted approval in September 2024.

This delayed launch means Eli Lilly had less time to build out distribution compared to competitors like Dupixent, which has been on the market since 2017. The manufacturing concerns have been fully resolved, and there are no ongoing quality or safety issues with the drug itself.

Final Thoughts

While Ebglyss is not in a formal shortage in 2026, its limited specialty pharmacy distribution, recent market entry, and insurance hurdles make it harder to access than many patients expect. The key is working with your healthcare team, using tools like Medfinder to check stock, and planning ahead for refills.

Your eczema treatment shouldn't be held up by logistics. Stay proactive, explore all your options, and don't hesitate to reach out to Eli Lilly's support programs if cost is a barrier.

Have questions about side effects? Read Ebglyss side effects: what to expect.